Profound Medical Corp. closed at $6.87 per share on June 18, 2026, with a one-month return of 0.51% and a 52-week gain of 8.11%. Grow Funds highlighted the company in its first-quarter 2026 investor letter, noting its TULSA-PRO system is installed at 78 marquee hospitals with a pipeline of over 110 systems. The fund also pointed to higher hospital reimbursement compared to competitive procedures and favorable results from the Captain Trial versus radical prostatectomy. However, hedge fund holdings in Profound Medical fell to 6 at the end of the first quarter from 10 in the prior quarter, and the stock was not among the 40 most popular hedge fund stocks heading into 2026.
Profound Medical CorpTULSA-PRO system installed at 78 marquee hospitals with pipeline of over 110 systems, higher reimbursement, and favorable trial results